恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

callispheres®载药微球经动脉化疗栓塞治疗275例肝细胞癌患者的疗效和安全性:ctilc的研究结果-ag捕鱼平台

文字: 2019-11-13    浏览次数:419    

abstract

the purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (deb-tace) treatment in chinese hepatocellular carcinoma (hcc) patients and the prognostic factors for treatment response as well as survival.

 本研究旨在探讨载药微球经动脉化疗栓塞(deb-tace)治疗中国肝细胞癌(hcc)患者的疗效和安全性,以及影响治疗反应和生存的预后因素。

 

a total of 275 hcc patients were included in this prospective study. treatment response was assessed by modified response evaluation criteria in solid tumors (mrecist), and progression-free survival (pfs) as well as overall survival (os) were determined. liver function and adverse events (aes) were assessed before and post deb-tace operation.

 本前瞻性研究共纳入了275hcc患者。采用改良的实体瘤反应评估标准(mrecist)评估治疗反应,确定无进展生存期(pfs)和总生存(os)。在deb-tacecallispheres®载药微球)术前和术后评估肝功能和不良事件(aes)

 

complete response (cr), partial response (pr), and objective response rate (orr) were 22.9%, 60.7%, and 83.6%, respectively. the mean pfs was 362 (95%ci: 34.9-375) days, the 6-months pfs rate was 89.4%±2.1%, while the mean os was 380 (95% ci: 370-389) days, and the 6-month os rate was 94.4%±1.7%.multivariate logistic regression revealed that portal vein invasion (p=0.011) was an independent predictor of worse clinical response. portal vein invasion (p=0.040), previous ctace treatment (p=0.030) as well as abnormal serum creatinine level (bcr) (p=0.017) were independent factors that predicted for worse orr. in terms of survival, higher barcelona clinic liver cancer (bclc) stage (p=0.029) predicted for worse pfs, and abnormal albumin (alb) (p=0.011) and total serum bilirubin (tbil) (p=0.009) predicted for worse os. the number of patients with abnormal albumin, total protein (tp), tbil, alanine aminotransferase (alt), and aspartate aminotransferase (ast) augmented at 1 week post treatment and were similar at 1-3 months compared with baseline. the most common aes were pain, fever, nausea and vomiting, and no severe aes were observed in this study.

完全缓解(cr)、部分缓解(pr)和客观缓解(orr)分别为22.9%60.7%83.6%。平均pfs362(95%ci: 34.9-375) 6个月pfs89.4%±2.1%,平均os380(95%ci: 370-389) 6个月os94.4%±1.7%。多因素logistic回归分析显示,门静脉侵犯(p=0.011)是临床反应较差的独立预测因素。门静脉侵犯(p=0.040)、既往ctace治疗史(p=0.030)和血清肌酐水平(bcr)异常(p=0.017)是预测orr恶化的独立因素。在生存方面,巴塞罗那临床肝癌(bclc)分期越高(p=0.029)预示着pfs越差,白蛋白(alb)存在异常(p=0.011)以及总胆红素(tbil)异常(p=0.009)预示着os越差。治疗后1周白蛋白、总蛋白(tp)tbil、丙氨酸转氨酶(alt)、天冬氨酸转氨酶(ast)异常的患者数较基线时增加,治疗后1-3个月与基线相似。最常见的aes是疼痛、发热、恶心和呕吐,本研究未发现有严重的aes

 

deb-tace was effective and tolerable in treating chinese hcc patients, and portal vein invasion, previous ctace treatment, abnormal bcr, alb and tbil appear to be important factors that predict for worse clinical outcome.

deb-tace治疗中国hcc患者有效且可耐受,门静脉侵犯、既往ctace治疗,以及bcralbtbil异常是较差临床结局的重要预测因素。